Science & Innovation Theaters: Program Details

April 11, 2024

View descriptions of the many Science & Innovation Theaters taking place at ENDO 2024!

Program Schedule


Saturday, June 1
10:00-11:00 AM ET
Theater #2

Sponsor Alexion, AstraZeneca Rare Disease

Spotlight on Hypophosphatasia: Shining a Light on Your Adult Patients

Description: Hypophosphatasia (HPP) is a rare, inherited, metabolic disorder caused by tissue-nonspecific alkaline phosphatase (TNSALP) deficiency.  In adult patients with HPP, commonly reported symptoms include musculoskeletal pain, recurrent and poorly healing fractures, and dental abnormalities.  Due to the variability of the clinical presentation, the diagnosis is often missed or delayed for up to 25 years before an adult patient may receive an HPP diagnosis.

During the product theater, Dr. Rosen will provide a general introduction to HPP and moderate the overall discussion while Dr. Dahir will emphasize the importance of recognizing HPP in adults (and not solely in children) and the evolving landscape of diagnosis in adults with HPP.  With a goal to improve healthcare professionals’ diagnosis of HPP and drawing on the latest research and support tools, Dr. Dahir will discuss when to suspect HPP, the challenges of diagnosing HPP, which tests to prioritize, the importance of early detection, and the profound impact on patient outcomes. She will present cases that exemplify the diagnostic journey in adult patients, focusing on both skeletal, as well as non-skeletal manifestations, and discuss lessons learned for future practice.

Speakers:

Kathryn Dahir, MD
Vanderbilt University Medical Center, Nashville, TN

Clifford Rosen, BS, MD
Maine Medical Center’s Research Institute, Scarborough, ME 


Saturday, June 1
12:30-1:30 PM ET
Theater #1

Sponsor: Eli Lilly and Company

Mounjaro® (tirzepatide) Product Theater

Description: Join a presentation from one of your peers to learn about Mounjaro, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes (T2D). This presentation will include a review of clinical efficacy and safety results, and how to get your adult patients with T2D started on Mounjaro. Attendees will have the opportunity to pose questions to the speaker at the end of the session. 

Please see the Important Safety Information for Mounjaro, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the Full Prescribing Information, and Medication Guide provided at the product theater. 

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Speaker:

Mark Warren, MD, FACE 


Saturday, June 1
12:30-1:30 PM ET
Theater #2

Sponsor: Corcept Therapeutics

Perspectives in Hyperglycemia Secondary to Hypercortisolism – A Path to Diagnosis

Description: Case-based panel discussion on evolving perspectives in endogenous Cushing Syndrome

Speakers:

Richard Auchus, MD, PhD
Professor of Internal Medicine and Endocrinology
University of Michigan
Ann Arbor, MI

James W Findling MD
Professor of Medicine and Surgery
Division of Endocrinology and Molecular Medicine
Medical College of Wisconsin
Milwaukee, WI


Saturday, June 1
12:30-1:30 PM ET
Theater #3

Sponsor: Acella Pharmaceuticals

Treating Hypothyroidism: Two Researchers’ Perspectives on the Changing Landscape of Hypothyroidism Treatment

Description: Join international experts Elizabeth McAninch, MD and Thanh Hoang, DO, FACP, FACE as they discuss their scientific journeys that led them to focus on hypothyroidism and the patient with persistent clinical symptoms.

Speakers:

Elizabeth A. McAninch, MD
Clinical Associate Professor, Medicine
Stanford University School of Medicine
Palo Alto, CA

Thanh D. Hoang, DO, FACP, FACE
Program Director, NCC Endocrinology Fellowship Program
Professor, Uniformed Services 
University of the Health Sciences
Division Director, Endocrine Division 
Uniformed Services University of the Health Sciences
Bethesda, MD


Saturday, June 1
3:15-4:15 PM ET
Theater #1

Sponsor: Recordati Rare Diseases, Inc

Examining the Puzzle of Cushing Disease

Description: This interactive panel discussion highlights key topics in Cushing disease, based on feedback from a survey of endocrinologists. 

  • Highlighting the impact of diagnostic delay, and recognition of symptoms that raise suspicion of Cushing syndrome, the first step in identifying Cushing disease, and considerations for testing.
  • The panel will explore the algorithm for diagnosis of Cushing disease and the role of diagnostic tools.
  • Elucidate the complexities persistent and recurrent Cushing disease and the importance of clinical and biochemical endpoints in defining treatment response.

Moderator:

Atil Kargi, MD
Professor of Neurosurgery and Medicine, Co-Director of Pituitary Center in Department of Neurosurgery
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Speakers:

Oksana Hamidi, DO
Associate Professor, Division of Endocrinology and Metabolism
University of Texas Southwestern Medical Center
Dallas, Texas

Catherine D Zhang, MD
Assistant Professor of Medicine, Division of Endocrinology and Molecular Medicine Medical College of Wisconsin
Milwaukee, Wisconsin


Saturday, June 1
3:15-4:15 PM ET
Theater #2

Sponsor: Crinetics Pharmaceuticals

Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly

Description: Acromegaly is a rare chronic disease almost always caused by a pituitary adenoma that secretes excess growth hormone, resulting in hypersecretion of IGF-I, predominantly by the liver. Medical therapy is recommended when surgery fails to achieve remission and for patients who are not suitable candidates for surgery. Somatostatin receptor ligands (SRLs), octreotide and lanreotide, administered by injection are first-line medical treatment for acromegaly.  However, there are treatment challenges and high burden of treatment with currently available SRLs. These include poor symptom control, specifically worsening of symptoms at the end of each injection cycle, as well as treatment-related injection site reactions and pain associated with monthly injections often administered in a doctor’s office.  There is a clear need for new reliable treatment options that reduce the burden of care for patients. This program will discuss paltusotine, a novel, investigational once-daily, oral, selectively targeted nonpeptide SRL.  Results from the PATHFNDR-1 Phase 3 study in patients with acromegaly switched from injected SRL monotherapy to once-daily oral paltusotine will be presented. Paltusotine is an investigational drug and has not yet been filed or approved for marketing authorization. 

Speaker:

Kevin C.J. Yuen, MBChB, MD, FRCP, FACE 
Barrow Neurological Institute, Phoenix, AZ 


Saturday, June 1
3:15-4:15 PM ET
Theater #3

Sponsor: Sanofi TZIELD

Explore Advancements in Type 1 Diabetes Management 

Description: Type 1 diabetes (T1D) can have a devastating impact on both patients and their loved ones. Explore advancements in T1D management and the importance of proactive screening, particularly among individuals at increased risk for T1D. Join us to learn more about the paradigm shift in caring for patients with T1D.

Speaker:

Jason Baker, MD
Weill Cornell Medicine
New York, NY


Sunday, June 2
9:30-10:30 AM ET
Theater #1

Sponsor: Tolmar Inc.

The State of TRT: Feeling the impact of trends in practice and patient care

Description: Join us for a presentation and discussion on the results of an inaugural landmark TRT Sermo survey of 303 Endocrinologists, Urologists, PCPs and other specialists sponsored by JATENZO® (testosterone undecanoate) capsules.
Leading experts will explore key testosterone replacement therapy (TRT) insights, trends and common myths for endocrinologists and other specialties, including:

  • Understanding TRT patient experience and unmet needs
  • Prescribing behaviors and barriers across multiple specialties
  • Myths and opportunities for patient and peer education

This presentation is funded by, and is being presented on behalf of, Tolmar Pharmaceuticals, Inc. (“Tolmar”). All information about any Tolmar Product is consistent with approved product labeling. This program is not approved for CME credits. 

Speakers:

Dr. Adrian Dobs, MD MHS
Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine
Baltimore, MD

Dr. Sandeep Dhindsa, M.B.B.S
Chief, Division of Endocrinology and Metabolism, Saint Louis University
SLUCare Academic Pavilion
St. Louis, MO


Sunday, June 2
9:30-10:30 AM ET
Theater #2

Sponsor: Ascendis Pharma A/S

Perspectives on a once-weekly growth hormone for pediatric growth hormone deficiency

Description: A physician speaker will review the clinical data and differentiating features of a once-weekly growth hormone used to treat pediatric growth hormone deficiency. Following the clinical presentation, a caregiver ambassador will tell their child and family’s journey from diagnosis to treatment with a once-weekly growth hormone.


Sunday, June 2
9:30-10:30 AM ET
Theater #3

Sponsor: Rhythm Pharmaceuticals

Acquired Hypothalamic Obesity: A Distinct, Form of Obesity Associated with MC4R Pathway Impairment.

Description: One hour symposium to educate attendees on the melanocortin-4 receptor (MC4R) pathway, its role in certain rare forms of obesity, and the treatment journey of patients with hypothalamic obesity: an acquired form of obesity distinct from general obesity.


Sunday, June 2
12:00-1:00 PM ET
Theater #1

Sponsor: Pfizer

Pfizer’s Latest LAGH in pGHD Treatment: A Clinical Overview and Deep Dive into IGF-1 Monitoring

Description: Pfizer has been committed to the pediatric growth hormone deficiency (pGHD) community for over 30 years. We welcome you to learn more about Pfizer’s latest advancement in pGHD Treatment and how to appropriately interpret patients' IGF-1 levels for it its once-weekly dosing regimen. 

Speakers:
Lawrence A. Silverman, MD
Board Certified Pediatric Endocrinologist
Atlantic Medical Group
Morristown Medical Center
Overlook Medical Center
Morristown, NJ 

Aristides K. Maniatis, MD, FAAP
Board Certified Pediatric Endocrinologist
Presbyterian/St. Luke’s Medical Center
Swedish Medical Center
Rocky Mountain Pediatric Endocrinology
Centennial, CO


Sunday, June 2
12:00-1:00 PM ET
Theater #2

Sponsor: Dexcom

Maximizing Dexcom's Potential: Advancing Diabetes Care in Type 1 and Type 2 Diabetes

Description: In the swiftly evolving landscape of healthcare technology and accessibility, the care of diabetes can be even more personalized.  This program is designed to inform healthcare professionals about the revolutionary role that real-time continuous glucose monitoring (RT-CGM) plays in enhancing diabetes management.

Come join us for an insightful presentation where we explore the cutting-edge developments in Dexcom CGM in T1D and T2D. We'll provide a comprehensive overview of the current commercially available Dexcom-enabled AID systems, explore Dexcom G7, and discuss real-world research findings. 

Discover how RT-CGM can be an integral part of diabetes management to help improve glycemic outcomes and support customizable treatment options for your patients.

Speakers:
 
Dr. Viral Shah MD 

Professor of Medicine, Division of Endocrinology & Metabolism
Director of Diabetes Clinical Research, IU Center for Diabetes and Metabolic Diseases

Dr. Halis Kaan Akturk MD 
Associate Professor of Medicine and Pediatrics
Barbara Davis Center for Diabetes, University of Colorado


Sunday, June 2
12:00-1:00 PM ET
Theater #3

Sponsor: AMGEN

Thyroid Eye Disease (TED): Early Diagnosis and Treatment

Description: Learn about the heterogeneous presentation of Thyroid Eye Disease (TED), importance of early identification, and how endocrinologists can contribute to the care of patients with TED in the evolving treatment landscape.

Speaker:

Todd Frieze


Sunday, June 2
2:30-3:30 PM ET
Theater #1

Sponsor: Kyowa Kirin

Recognizing the Rare: X-Linked Hypophosphatemia (XLH) Diagnosis and Patient Perspectives

Description: X-linked hypophosphatemia (XLH) is a rare genetic metabolic bone disease that often involves a long road to diagnosis and management. Early diagnosis and management in adults with XLH is critical to skeletal health. Join us for a discussion of the hallmark features of XLH, the importance of screening for low phosphorus, and management of XLH.

This product theater is sponsored by Kyowa Kirin, Inc. This presentation is intended for US-based health care providers. 

Speakers:

Faculty Presenter:

Dr. Laila Tabatabai, MD
Associate Professor of Clinical Medicine, Academic Institute Houston Methodist
Weill Cornell Medical College Houston, TX

Patient Ambassador:

Aly
San Antonio, TX


Sunday, June 2
2:30-3:30 PM ET
Theater #2

Sponsor: Alexion, AstraZeneca Rare Disease

An Overview of Hypophosphatasia (HPP)

Description: Recognize the signs, symptoms, and burden of hypophosphatasia, as well as the importance of a timely diagnosis

Speaker:

Eric T. Rush, MD, FAAP, CCD
Clinical Geneticist
Underdown/Yeomans Endowed Professor Medical Director
Children's Mercy Hospital, University of Kansas Health System
Kansas City, MO


Sunday, June 2
2:30-3:30 PM ET
Theater #3

Sponsor: Ionis Pharmaceuticals

Familial Chylomicronemia Syndrome (FCS): recognizing, diagnosing, and managing an overlooked genetic form of severe hypertriglyceridemia (sHTG)


Monday, June 3
9:30-10:30 AM ET
Theater #1

Immunovant

Sponsor: Immunovant

An Update on Graves’ Disease and Associated Thyroid Eye Disease

Description: Graves’ disease is an autoimmune disease driven by thyroid-stimulating hormone receptor (TSHR) autoantibodies, which can impact multiple organ systems and lead to extra-thyroidal manifestations such as thyroid eye disease (TED). Despite current standard of care, patients may be poorly controlled or relapse, resulting in a negative impact on a patient health and quality of life. Faculty will discuss the current understanding of the pathogenesis of Grave’s Disease and associated TED, burden of disease, disease epidemiology, and unmet patient needs.


Monday, June 3
9:30-10:30 AM ET
Theater #2

Sponsor: Eli Lilly and Company


Monday, June 3
9:30-10:30 AM ET
Theater #3

Sponsor: Novo Nordisk Healthcare AG

Realizing the possibilities: expanding growth hormone treatment options

Description: Growth hormone deficiency is a rare disorder that develops as a result of insufficient secretion of growth hormone (GH). Effects of inadequate GH levels can be significant as GH is required for normal growth in children and for metabolism and body composition in children and adults. This program will discuss the treatment landscape in patients with growth hormone deficiency. The clinical characteristics of a product used to treat patients with growth hormone deficiency will also be presented.

Speakers:

Dr. Heidi C. Shea, MD, F.A.A.P, F.A.C.E
Endocrine Associates of Dallas, PA
Plano, Texas

Dr. Dr. Joshua H. Yang, MD
Orlando Health Arnold Palmer Hospital for Children Endocrinology and Diabetes Center
Orlando, Florida


Monday, June 3
12:30-1:30 PM ET
Theater #1

Sponsor: QuidelOrtho

TSH Receptor Antibodies – Methodological Progress & Clinical Relevance

Description: The role of thyrotropin receptor autoantibodies (TSH-R-Ab) in the pathogenesis of autoimmune hyperthyroidism or Graves’ disease (GD) is well established. Recent advances in biosensors have been applied to the development of TSH-R-Ab bioassays that are rapid and simple to perform. A novel cell-based bioassay, referred to as Turbo TSITM, for measurement of thyroid-stimulating autoantibodies (TSAb) was recently developed. Turbo TSI greatly reduces the complexity and time required to measure TSAb. It avoids the need for cell culture, has no wash or lysis steps, and has a total turn-around-time of less than 90 minutes. Hence, we now are entering an era in which bioassays for TSH-R-Ab can be measured routinely by virtually any clinical laboratory.

Speakers:

Paul D Olivo, MD, PHD
St. Louis, MO, USA 

George J Kahaly, MD, PHD
Mainz, Germany 

Moderator:
George J Kahaly, MD, PHD
Mainz, Germany 


Monday, June 3
12:30-1:30 PM ET
Theater #2

Sponsor: Eli Lilly and Company

Product Theater for Zepbound (tirzepatide) Injection

Description: Join a presentation from one of your peers on the efficacy and safety of once-weekly Zepbound, and learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to pose questions to the speaker at the end of the session. Refreshments will be provided.

Please see the Important Safety Information for Zepbound, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the full Prescribing Information, and Medication Guide provided at the Product Theater. 

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Speaker:

Tamer Yacoub, MD, FACE


Monday, June 3
12:30-1:30 PM ET
Theater #3

Sponsor: Rhythm Pharmaceuticals

Targeting Impairment in the MC4R Pathway a root cause of hyperphagia and obesity in Bardet Biedl syndrome (BBS)

Description:

  • Hyperphagia and Obesity due to BBS - the difference from general obesity 
  • Understanding BBS and its diagnosis
  • A treatment that significantly reduced measures of weight and hunger in BBS clinical trials
  • Caregiver perspective 

 

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.